Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

• Post author:andrewkaretas
• Post published:December 15, 2025
• Post category:Latest News

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China , Clearing the Path…

Continue ReadingAllogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:November 19, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

144: Filed by “insiders” prior intended sale of restricted stock.

• Post author:andrewkaretas
• Post published:November 17, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock.

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:November 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:November 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:November 12, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

10-Q: Quarterly report which provides a continuing view of a company’s financial position

• Post author:andrewkaretas
• Post published:November 6, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading10-Q: Quarterly report which provides a continuing view of a company’s financial position

8-K: Report of unscheduled material events or corporate event

• Post author:andrewkaretas
• Post published:November 6, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event

4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:October 23, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

• Post author:andrewkaretas
• Post published:October 23, 2025
• Post category:Twitter

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue ReadingPlease join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO